Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
Launched by IRCCS BURLO GAROFOLO · Mar 20, 2025
Trial Information
Current as of April 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain tests can help predict heart injuries in children and teenagers receiving a specific type of cancer treatment called Anthracycline chemotherapy. Researchers are looking at echocardiography, which is a type of ultrasound that checks how well the heart is working, and blood tests that measure heart-related proteins. This study aims to find out if these tests can help identify heart problems early in young patients who are about to start their treatment.
To participate in the trial, children and teenagers aged 0 to 18 who have been diagnosed with cancer and are starting Anthracycline therapy may be eligible, but they must have normal heart function before starting the treatment. However, those who have had previous treatments with Anthracycline, bone marrow transplants, or certain heart conditions will not be included. Participants can expect to undergo heart tests before and during their treatment, which will help doctors understand the effects of the chemotherapy on their heart health. This information could be important for ensuring safer cancer treatment in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Paediatric oncological patients 0-18 years
- • Planned start of anthracycline therapy
- • Normal left ventricular systolic function according to International Guidelines before the treatment with AC
- Exclusion Criteria:
- • Previous anthracycline treatment, bone marrow transplantation or chest radiation
- * Pre-anthracycline treatment echocardiographic evidence of:
- • More than mild pericardial effusion
- • More than mild mitral regurgitation
- • Poor echocardiographic acoustic window
Trial Officials
Thomas Caiffa, MD
Principal Investigator
IRCCS Burlo Garofolo
About Irccs Burlo Garofolo
IRCCS Burlo Garofolo is a prestigious research institute located in Trieste, Italy, dedicated to advancing pediatric healthcare through innovative clinical research. As a recognized IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it focuses on a wide range of pediatric diseases, emphasizing the integration of clinical care and scientific research to improve patient outcomes. The institute collaborates with various national and international partners, fostering an environment of rigorous scientific inquiry and excellence in medical practice. Its commitment to ethical standards and patient safety ensures that all clinical trials conducted under its auspices contribute meaningful advancements in pediatric medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trieste, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported